Results
Symbiotec Pharmalab Q1 FY27 Earnings Call Highlights Growth
Symbiotec Pharmalab held its Q1 FY27 earnings call, providing a transcript as a regulatory disclosure per SEBI LODR regulations.
Management provided FY27 guidance targeting 20% revenue growth and 25%
